In a study on patients with MPN (n = 391), JAK2 V617F mutation-positive subjects were more susceptible to thrombotic events than JAK2 V617F-negative subjects, which is statistically significant among ET (p < 0.01) and PMF groups (p < 0.01) [41]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.